Firms Will Get Heads-Up Before Products Land on FDA's Proposed Drug Watch

Executive Briefing Series
A A

The FDA will alert pharmaceutical companies shortly before their products are placed on the agency’s proposed Drug Watch website for emerging drug-safety concerns, but firms will not be able to appeal or influence the agency’s decisions regarding the site, according to FDA officials.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $10.00